Who we are

Seagen is a global biotechnology company dedicated to developing revolutionary therapies with real impact.

Seagen global biotech company
Seagen vision

Our vision

Improving the lives of people with cancer through innovative targeted therapies

Seagen mission

Our mission

To discover, develop, and commercialize transformative cancer medicines to make a meaningful difference in people’s lives

Our values

Seagen values patients

Passion for helping patients

Revolutionizing therapy for people living with cancer

Seagen values integrity


Honesty, respect, and trust guide us

Seagen values scientific excellence

Scientific excellence

Premier science empowers our passion

Seagen values respect

Teamwork and mutual respect

Shared dedication drives successful collaborations

Seagen values innovation


Entrepreneurial spirit advances breakthrough therapies

Seagen values purpose

Great work environment

Commitment and opportunity inspire purposeful contribution

Who We Are

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.

As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies to deliver cell-killing agents directly to cancer cells. This technology is the foundation of two of our approved medicines—ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv).

Today, our research efforts are focused on advancing a pipeline of novel targeted therapies, including TUKYSA® (tucatinib), recently approved for certain metastatic HER2+ breast cancers. We’re also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.